Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902713 | 0.89 | PKM (0.52) | PKMMAPK1HTTALDH1A1MEN1 | |
| SCHEMBL4906988 | 0.88 | MEN1 (0.47) | PKMMAPK1HTTALDH1A1MEN1 | |
| SCHEMBL4897508 | 0.88 | PKM (0.54) | PKMMAPK1HTTALDH1A1MEN1 | |
| SCHEMBL4905473 | 0.87 | ALDH1A1 (0.59) | PKMMAPK1HTTALDH1A1MEN1 | |
| SCHEMBL4902988 | 0.87 | PKM (0.50) | PKMMAPK1HTTALDH1A1MEN1 | |
| SCHEMBL4906759 | 0.86 | PKM (0.55) | PKMMAPK1HTTALDH1A1MEN1 | |
| SCHEMBL4899302 | 0.85 | MAPT (0.57) | MEN1KMT2ATP53AKR1C3 | |
| SCHEMBL4898272 | 0.85 | ALDH1A1 (0.63) | PKMMAPK1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL4904026 | 0.85 | ALDH1A1 (0.57) | PKMMAPK1HTTALDH1A1MEN1 | |
| SCHEMBL4903809 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101287718-A | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER PROD INC (US) | 2008-10-15 | — | — | CN | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| EP-1765796-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | Pfizer Products Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| WO-2006003495-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | PKM 896/4885MAPK1 3332/4885HTT 711/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | PKM 861/4885MAPK1 3366/4885HTT 696/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | PKM 861/4885MAPK1 3366/4885HTT 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.